Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome

Exclusion Criteria

• •Sjögren's Syndrome overlap syndromes where another autoimmune rheumatic disease constitutes the principle illness
• •Use of other investigational drugs
• •Prior use of B cell depleting therapies, abatacept or any other immunosuppressants unless specifically allowed be the protocol.
• •Use of steroids at dose \>10 mg/day.
• •Uncontrolled ocular rosacea (affecting the eye adnexa), posterior blepharitis or Meibomian gland disease (this criterion applies only to patients considered for Cohort 2)
• •Active viral, bacterial or other infections requiring systemic treatment
• •Receipt of live/attenuated vaccine within a 2-month period prior to randomization.
• •Chronic infection with hepatitis B (HBV) or hepatitis C (HCV).
• •Evidence of active tuberculosis (TB) infection.